Informations:
Erreur:
ID
16817
Description
CFAR Study in Patients With Chronic Lymphocytic Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT00525603
Lien
https://clinicaltrials.gov/show/NCT00525603
Mots-clés
Versions (1)
- 08/08/2016 08/08/2016 -
Téléchargé le
8 août 2016
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY 4.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Eligibility Leukemia NCT00525603
Eligibility Leukemia NCT00525603
- StudyEvent: Eligibility
Similar models
Eligibility Leukemia NCT00525603
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Untreated chronic lymphocytic leukemia
Item
all patients must have a diagnosis of cll by immunophenotyping and flow cytometry analysis of blood or bone marrow and be previously untreated.
boolean
C0023434 (UMLS CUI [1,1])
C0332155 (UMLS CUI [1,2])
C0332155 (UMLS CUI [1,2])
Age, serum beta-2 microglobulin
Item
all patients must be younger than 70 years and have a serum beta-2 microglobulin of >/= 4.0mg/l.
boolean
C0001779 (UMLS CUI [1])
C0201910 (UMLS CUI [2])
C0201910 (UMLS CUI [2])
Rai stage
Item
all patients with rai stage iii-iv are eligible for treatment on this protocol. - or- all patients with rai stage 0-ii who meet one or more indication for treatment as defined by the nci-sponsored working group are eligible for treatment on this protocol.
boolean
C1514715 (UMLS CUI [1])
Zubrod Performance Status
Item
all patients must have a zubrod performance status of 0-3.
boolean
C3714786 (UMLS CUI [1])
renal and hepatic function
Item
all patients must have adequate renal and hepatic function (serum creatinine </= 2mg/dl; total bilirubin </= 2.5mg/dl). patients with renal or liver dysfunction due to organ infiltration by lymphocytes may be eligible after discussion with the principle investigator and appropriate dose adjustment considered.
boolean
C0201976 (UMLS CUI [1])
C0201913 (UMLS CUI [2])
C0201913 (UMLS CUI [2])
Concurrent Chemotherapy, Radiotherapy, or Immunotherapy
Item
patients may not receive concurrent chemotherapy, radiotherapy, or immunotherapy. localized radiotherapy to an area not compromising bone marrow function does not apply, nor do hematopoietic growth factors such as erythropoietin, granulocyte colony-stimulating factor (g-csf), granulocyte-macrophage colony stimulating factor (gm-csf), etc.
boolean
C0009429 (UMLS CUI [1,1])
C0392920 (UMLS CUI [1,2])
C0009429 (UMLS CUI [2,1])
C1522449 (UMLS CUI [2,2])
C0009429 (UMLS CUI [3,1])
C0021083 (UMLS CUI [3,2])
C0392920 (UMLS CUI [1,2])
C0009429 (UMLS CUI [2,1])
C1522449 (UMLS CUI [2,2])
C0009429 (UMLS CUI [3,1])
C0021083 (UMLS CUI [3,2])
Infection
Item
patients must not have untreated or uncontrolled life-threatening infection.
boolean
C0009450 (UMLS CUI [1])
Informed consent
Item
patients must sign informed consent.
boolean
C0021430 (UMLS CUI [1])
Age
Item
patients older than 70 years.
boolean
C0001779 (UMLS CUI [1])